Sign in
Taking peopleNo phase

TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage

Key facts

Who runs it
Xuanwu Hospital, Beijing
Where
China70 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
750 people, planned
Started
24 Oct 2025
Expected to end
1 Mar 2028
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Early Minimally Invasive Surgery with Thrombolysis (eMIST)
Record updated
20 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Pre-randomization head CT demonstrating an acute, spontaneous, primary ICH
  • ICH volume ≥ 20mL as calculated by the ABC/2 method
  • The randomization can be completed within 8 hours after the onset of stroke symptoms (or the time last known to be well), and study intervention can reasonably be initiated within 4 hours after randomization
  • Historical Modified Rankin Score 0 or 1
  • Obtain informed consent from patient or legal representative

Who cannot take part

  • Use of 2 or more antithrombotic drugs prior to symptom onset
  • Any concurrent serious illness that would interfere with the outcome assessments including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, and hematologic disease
  • Participation in a concurrent interventional medical investigation or clinical trial
  • Infratentorial intraparenchymal hemorrhage including midbrain, pontine, or cerebellar
  • Ruptured aneurysm, arteriovenous malformation (AVM), vascular anomaly, Moyamoya disease, venous sinus thrombosis, mass or tumor, hemorrhagic conversion of an ischemic infarct, tumor stroke, recurrence of a recent (<1 year) ICH, as diagnosed with radiographic imaging
  • Hemorrhage with apparent midbrain extension with third nerve palsy or dilated and non-reactive pupils. Other (supranuclear) gaze abnormalities are not exclusions
  • Intraventricular extension of the Hemorrhage is visually estimated to involve >50% of either of the lateral ventricles
  • Any irreversible coagulopathy or known clotting disorder
  • Patients with a mechanical heart valve
  • Urokinase allergy
  • Platelet count < 750,000, INR > 1.4 after correction
  • Positive urine or serum pregnancy test in female subjects without documented history of surgical sterilization or is post-menopausal
  • Presence of spot sign in CT angiography
  • Blood pressure control before randomization is ineffective, systolic blood pressure > 220 mmHg
  • Irreversible impaired brain stem function (bilateral fixed, dilated pupils and extensor motor posturing), GCS ≤ 4
  • Patients requiring long-term anti-coagulation that needs to be initiated < 30 days from index ICH
  • Inability or unwillingness of patient or legal representative to give written informed consent
  • Known life-expectancy of less than 6 months

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

TIME-ICH (TrIal of early Minimally Invasive catheter Evacuation with thrombolysis in IntraCerebral Hemorrhage) is a multicenter, randomized, adaptive clinical trial comparing best medical management to early minimally invasive surgery with thrombolysis (eMIST) in the treatment of acute spontaneous supratentorial intracerebral hemorrhage.

The 2 groups in the trial

  • Early Minimally Invasive Surgery with Thrombolysis (eMIST) plus best medical management (BMM)Treatment being tested

    Subjects will undergo minimally invasive catheter evacuation followed by up to 10 doses of 50000U of urokinase for intracerebral hemorrhage clot resolution.

    Treatment: Early Minimally Invasive Surgery with Thrombolysis (eMIST)

  • Best medical management (BMM)No study treatment, for comparison

    Subjects will receive standard of care medical management for ICH.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage (TIME-ICH): A Prospective, Multi-center, Open-label, Adaptive, Randomized Controlled Trial
Record updated
20 October 2026